Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies.
Cooper
David S
DS
Division of Endocrinology, Sinai Hospital of Baltimore, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21215, USA. dcooper@lifebridgehealth.org
D000328:Adult; D013956:Antithyroid Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D005104:Expert Testimony; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D016239:MEDLINE; D008713:Methimazole / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D008875:Middle Aged; D010349:Patient Compliance; D011441:Propylthiouracil / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013960:Thyroid Function Tests
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D008713:Methimazole; D011441:Propylthiouracil